The deal was Novo Nordisk’s bid to grab back market share from the cheaper, knockoff versions that Hims & Hers and other ...

Novo Nordisk today announced sales and operating profit growth at constant exchange rates (CER) for the first six months of ...

Shares in the $247 bln obesity drugmaker fell over 20% after it said sales would grow more slowly than expected. Competition ...

Novo Nordisk today announced that Maziar Mike Doustdar has been appointed as president and chief executive officer, effective ...

The maker of GLP-1 drugs Ozempic and Wegovy cut sales grown from 13%-21% down to 8%-14% for the year. That's about half, on the higher end, of the 26% growth seen in 2024. Outgoing CEO Lars Jøregensen ...

President Trump escalated efforts to reduce drug prices in the US on Thursday, releasing letters sent to 17 pharmaceutical ...

Novo Nordisk A/S’s best-sellers Ozempic and Wegovy transformed the firm into a global pharmaceutical giant. But four years ...

Global stocks weakened on Friday after Donald Trump hit dozens of countries with tariffs, as the US president pushed ahead ...

GLP-1 receptor agonists are an important drug class and have become widely popular due to their effectiveness in weight ...

If you suffered losses exceeding $50,000 in Hims between April 29, 2025 and June 22, 2025 and would like to discuss your ...

What Happened? On April 29, 2025, Hims announced a long-term collaboration with Novo Nordisk, starting with the immediate sale of“a bundled offering of Novo Nordisk's FDA-approved Wegovy on the Hims & ...

World markets have hunkered down for three days of economic health checks, corporate readouts and policy decisions that may ...